跳至主要内容
临床试验/CTIS2024-511172-33-00
CTIS2024-511172-33-00招募中1 期

A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects with Gaucher Disease (GALILEO-2) - FLT201-02

Freeline Therapeutics Limited0 个研究点目标入组 5 人开始时间: 2024年2月15日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • 1. Participants who have previously received FLT201 (including those who may have required recommencement or initiation of ERT/substrate reduction therapy [SRT])., 2. Participants able to give full informed consent and able to comply with all requirements of the trial.

排除标准

  • Not applicable.

研究者

相似试验

进行中(未招募)
1 期
A Long-term Follow-up Study of Fabry Disease Subjects Treated with FLT190 (MARVEL 2)Fabry disease
EUCTR2019-004645-32-DEFreeline Therapeutics Ltd50
进行中(未招募)
1 期
A Long-term Follow-up Study of Fabry Disease Subjects Treated with FLT190 (MARVEL 2)MedDRA version: 20.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry disease
EUCTR2019-004645-32-GBFreeline Therapeutics Ltd15
进行中(未招募)
不适用
A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset SeizuresEpilepsies PartialMedDRA version: 17.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disorders
EUCTR2014-004334-26-Outside-EU/EEACB Japan Co. Ltd398
招募中
1 期
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseMedDRA version: 20.0Level: LLTClassification code: 10001896Term: Alzheimer's disease Class: 10029205Alzheimer's Disease
CTIS2023-506872-29-00Alector LLC347
进行中(未招募)
不适用
Oral Revatio in Pediatric PAH - Long-term follow-on Study to A1481131.MedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary Arterial Hypertension
EUCTR2005-000963-25-Outside-EU/EEAPfizer Limited, Ramsgate Road, Sandwich, Kent, UK220